Web Analytics

3 Latest Announced Rounds

$1,325.73M Raised in 74 Funding Rounds in the past 7 Days - View All

Funding Round Profile

SynOx Therapeutics

start up
Ireland - Dublin City, County Dublin
  • 23/04/2024
  • Series B
  • $75,000,000

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Related People

Raymond BarlowFounder

Raymond Barlow United Kingdom - Oxford, England

I am a C-Suite Commercial Business Leader and Corporate Business Development Expert, developing and delivering organisational transformations for both start-up and leading global Life Sciences businesses to meet strategic goals.

As CBO of Kiadis Pharma NV I was brought on board to complete a strategic Licensing Agreement with Sanofi which led to the Company being acquired 4 month later at a 272% premium. As CEO of e-Therapeutics PLC I was brought on board to lead the public company turnaround and position the business for commercialisation. My earlier career includes: Executive Director at Amgen Inc, creating an international corporate development capability and transacting key deals; Senior Director at Crucell, professionalising the BD function to help enable the successful $2.3bn acquisition by Johnson & Johnson in 2011; and several years at AstraZeneca in various BD, commercial and scientific roles.

I can uniquely leverage my diverse scientific knowledge with my current commercial leadership experience across a wide range of organisations, while influencing operationally at board level as a Business Development subject matter expert, to optimise organisational expansion and global exposure.

I have a proven track record leading complex commercial negotiations including major mergers & acquisitions, licencing deals and business turnarounds. This includes driving business development and delivering transformational deals at Amgen to grow presence from 50 to 100 countries, improve product sales by 9% and achieve multiple commercial-stage deals including US rights to AIMOVIG.

Additionally, I nurture collaborative key senior stakeholder relationships to influence and ensure support for critical change.

My areas of expertise include:
☛ Global Business Development Leadership
☛ C-Suite Commercial Business Leadership
☛ Corporate Development
☛ Revenue & Profit Generation
☛ Business Turnaround
☛ Mergers & Acquisitions
☛ Transactional & Negotiation Expert
☛ Team Leadership
☛ Change Management
☛ Global Business Strategy Development
☛ Portfolio Rationalisation
☛ Business Integration